Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Avella Recalls Unexpired Nitroglycerin Products Due to Sub-Potency

By Avella Specialty Pharmacy | June 16, 2017

Advanced Pharma, Inc. d/b/a Avella of Houston issues voluntary nationwide recall of all unexpired NitroGlycerin Injection in 5% Dextrose USP products produced at its Houston location from March 3, 2017 through May 31, 2017 due to sub-potency.

Advanced Pharma, Inc. d/b/a Avella of Houston is voluntarily recalling all unexpired lots of nitroglycerin products that were produced at Advanced Pharma’s Houston location between March 3, 2017 and May 31, 2017 to the hospital/user level.  

The recall is being issued based on laboratory test results indicating a lower than expected potency on certain lots of compounded Nitroglycerin Injection which would lead to a lower dose being administered. While the lower than expected potency results affected only certain lots of nitroglycerin, in an abundance of caution, Advanced Pharma is recalling all unexpired lots of nitroglycerin. 

To date, Advanced Pharma has not received any reports of product complaints and/or adverse events related to the products.

Although nitroglycerin is titrated based on clinical response, an extreme and unexpected reduction in dose than expected could lead to a delay in treatment, disruption of clinical care of the patient, and worsening of patient’s conditions. 

Nitroglycerin Injection in 5% Dextrose, USP is indicated for treatment of high blood pressure before, during or after surgery; for control of heart failure after a heart attack; for treatment of heart related chest pain in patients who have not responded to nitroglycerin tablets taken under the tongue and other heart medicines; and to lower blood pressure during surgery.

The recalled nitroglycerin products include the 100 mcg per mL and 200 mcg per mL strengths available in 5 mL, 10 mL, and 20 mL sterile single dose syringes and are packaged in various sizes per carton. These products were not distributed directly to patients or consumers, but rather to healthcare facilities (e.g. hospitals) nationwide in the U.S. between March 9, 2017 to June 1, 2017 and have expiration dates (also known as “Beyond Use Dates” or “BUD”) ranging from June 9, 2017 to August 15, 2017.  

The issue is segregated to the Houston location and no other Avella locations are involved or affected.

Advanced Pharma has notified impacted customers of the voluntary recall by phone, email and overnight mail. Customers that have any of the affected medications that are being recalled should immediately discontinue use and return the unused portion to Avella.

Customers with any of the affected medications can also reference Advanced Pharma’s website for more information on the specific lot numbers affected, pictures of the product labels at issue and forms and contact information:  avella.com/ap-nitroglycerin-recall.  For a full list of products, please visit https://www.avella.com/sourceb-products.

Patients and healthcare providers with questions regarding this recall can contact the Advanced Pharma, Inc. recall line at (877) 292-4323, Monday through Friday, between 6 am and 6 pm (Pacific) or via e-mail at ProductRecall@avella.com. 

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

(Sources: PR Newswire; U.S. Food and Drug Administration)

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE